JAZZ Stock Analysis: Jazz Pharmaceuticals | NASDAQ

Narcolepsy, Epilepsy, Oncology, Leukemia

Total Rating 62

Safety 68

Buy Signal -0.24

Biotechnology
Industry Rotation: -19.5

Market Cap: 15.3B
Avg Turnover: 173M

Risk 3d forecast

Volatility34.4%

VaR 5^th Pctl5.71%

VaR vs Median0.80%

Reward TTM

Sharpe Ratio1.30

Rel. Str. IBD76.7

Rel. Str. Peer Group65.7

Character TTM

Beta0.499

Beta Downside-0.062

Hurst Exponent0.517

Drawdowns 3y

Max DD32.18%

CAGR/Max DD0.60

CAGR/Mean DD1.69

EPS (Earnings per Share)

EPS CAGR: -14.52%
EPS Trend: -29.9%

Last SUE: -0.10
Qual. Beats: 0

Revenue

Rev. CAGR: 6.57%
Rev. Trend: 96.4%

Last SUE: 1.94
Qual. Beats: 2

Warnings

Below Avwap Earnings

Tailwinds

No distinct edge detected

Seasonality 11.7 years of data

Jan -0.1% 7

Feb +0.6% 5

Mar +3.4% 20

Apr +2.0% 5

May -1.8% 10

Jun -0.8% 8

Jul +0.2% 19

Aug -1.6% 15

Sep -1.4% 28

Oct +0.0% 2

Nov -0.7% 11

Dec +0.1% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: JAZZ Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a Dublin, Ireland-based biopharmaceutical company founded in 2003 that identifies, develops, and commercializes pharmaceutical products across the United States, Europe, and international markets. The company operates within the specialty pharmaceuticals segment of the health care sector.

The companys commercial portfolio spans multiple therapeutic areas, including neuroscience (Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex for seizure disorders), oncology (Rylaze, Enrylaze, Zepzelca, Ziihera, Modeyso, Vyxeos), and rare diseases (Defitelio). This diversified product mix across specialty and rare-disease indications is characteristic of mid-to-large biopharma companies seeking to balance growth and pipeline risk.

The development pipeline includes late-stage assets such as Zanidatamab (Phase 3) for HER2-positive gastroesophageal and biliary tract cancers and Dordaviprone for H3 K27M-mutant diffuse glioma, alongside earlier-stage candidates like JZP815, JZP898, JZP047, and JZP3507 in Phase 1 and 2 trials.

Jazz supplements its internal R&D with collaboration and licensing agreements with partners including Redx Pharma, Autifony Therapeutics, Zymeworks, Sumitomo Pharma, Werewolf Therapeutics, and AbCellera Biologics - a hybrid in-house and partnership model commonly used in the biopharmaceutical industry to broaden pipelines without absorbing full development costs.

Headlines to Watch Out For

Xywav franchise faces generic erosion from Xyrem competition
Epidiolex revenue growth offsets narcolepsy segment decline
Zanidatamab Phase 3 HER2 cancer trial readout nears

Piotroski VR-10 (Strict) 6.0

Net Income: 940.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.14 > 0.02 and ΔFCF/TA 2.36 > 1.0
NWC/Revenue: 37.76% < 20% (prev 31.30%; Δ 6.46% < -1%)
CFO/TA 0.15 > 3% & CFO 1.66b > Net Income 940.8m
Net Debt (2.27b) to EBITDA (1.48b): 1.54 < 3
Current Ratio: 1.78 > 1.5 & < 3
Outstanding Shares: last quarter (69.4m) vs 12m ago 13.41% < -2%
Gross Margin: 84.67% > 18% (prev 88.71%; Δ -4.04% > 0.5%)
Asset Turnover: 41.78% > 50% (prev 37.34%; Δ 4.44% > 0%)
Interest Coverage Ratio: 4.74 > 6 (EBIT TTM 921.9m / Interest Expense TTM 194.4m)

Altman Z'' 2.73

A: 0.16 (Total Current Assets 3.97b - Total Current Liabilities 2.23b) / Total Assets 11.1b
B: 0.10 (Retained Earnings 1.13b / Total Assets 11.1b)
C: 0.08 (EBIT TTM 921.9m / Avg Total Assets 11.0b)
D: 0.76 (Book Value of Equity 4.80b / Total Liabilities 6.28b)
Altman-Z'' = 2.73 = A

Beneish M -2.87

DSRI: 1.10 (Receivables 880.9m/714.0m, Revenue 4.60b/4.09b)
GMI: 1.05 (GM 88.71% / 84.67%)
AQI: 0.92 (AQ_t 0.62 / AQ_t-1 0.67)
SGI: 1.13 (Revenue 4.60b / 4.09b)
TATA: -0.07 (NI 940.8m - CFO 1.66b) / TA 11.1b)
Beneish M = -2.87 (Cap -4..+1) = A

What is the price of JAZZ shares?

As of October 11, 2026, the stock is trading at USD 218.42 with a total of 1,288,280 shares traded. Over the past week, the price has changed by -7.32%, over one month by -9.49%, over three months by -11.54% and over the past year by +58.10%.

Current recommended Stop Loss: 209.60 (which is 4% or 1.3 ATR below the current price).

Is JAZZ a buy, sell or hold?

Jazz Pharmaceuticals has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy JAZZ.

StrongBuy: 13
Buy: 7
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the JAZZ price?

Analysts Target Price	294.3	34.7%

Jazz Pharmaceuticals (JAZZ) - Fundamental Data Overview as of 05 October 2026

Market Cap USD = 15.3b (15.3b USD * 1.0 USD.USD)
P/E Trailing = 16.1307
P/E Forward = 10.8932
P/S = 3.3248
P/B = 3.2539
P/EG = 0.9582
Revenue TTM = 4.60b USD
EBIT TTM = 921.9m USD
EBITDA TTM = 1.48b USD
Long Term Debt = 3.33b USD (from longTermDebt, last quarter)
Short Term Debt = 1.03b USD (from shortTermDebt, last quarter)
Debt = 4.47b USD (from shortLongTermDebtTotal, last quarter) + Leases 57.9m
Net Debt = 2.27b USD (calculated: Debt 4.47b - CCE 2.20b)
Enterprise Value = 17.6b USD (15.3b + Debt 4.47b - CCE 2.20b)
Interest Coverage Ratio = 4.74 (Ebit TTM 921.9m / Interest Expense TTM 194.4m)
EV/FCF = 11.39x (Enterprise Value 17.6b / FCF TTM 1.54b)
FCF Yield = 8.78% (FCF TTM 1.54b / Enterprise Value 17.6b)
FCF Margin = 33.52% (FCF TTM 1.54b / Revenue TTM 4.60b)
Net Margin = 20.45% (Net Income TTM 940.8m / Revenue TTM 4.60b)
Gross Margin = 84.67% ((Revenue TTM 4.60b - Cost of Revenue TTM 705.2m) / Revenue TTM)
Gross Margin QoQ = 90.37% (prev 71.34%)
Tobins Q-Ratio = 1.59 (Enterprise Value 17.6b / Total Assets 11.1b)
Interest Expense / Debt = 4.35% (Interest Expense 194.4m / Debt 4.47b)
Taxrate = 8.58% (18.1m / 211.0m)
NOPAT = 842.8m (EBIT 921.9m * (1 - 8.58%))
Current Ratio = 1.78 (Total Current Assets 3.97b / Total Current Liabilities 2.23b)
Debt / Equity = 0.93 (Debt 4.47b / totalStockholderEquity, last quarter 4.80b)
Debt / EBITDA = 1.54 (Net Debt 2.27b / EBITDA 1.48b)
Debt / FCF = 1.47 (Net Debt 2.27b / FCF TTM 1.54b)
Total Stockholder Equity = 4.40b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.54% (Net Income 940.8m / Total Assets 11.1b)
RoE = 21.37% (Net Income TTM 940.8m / Total Stockholder Equity 4.40b)
RoCE = 11.91% (EBIT 921.9m / Capital Employed (Equity 4.40b + L.T.Debt 3.33b))
RoIC = 8.73% (NOPAT 842.8m / Invested Capital 9.65b)
WACC = 6.89% (E(15.3b)/V(19.8b) * Re(7.74%) + D(4.47b)/V(19.8b) * Rd(4.35%) * (1-Tc(0.09)))
Discount Rate = 7.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 14.31 | Cagr: 4.74%
[DCF] Terminal Value 77.97% ; FCFF base≈1.43b ; Y1≈1.64b ; Y5≈2.41b
[DCF] Fair Price = 524.9 (EV 36.3b - Net Debt 2.27b = Equity 34.1b / Shares 64.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -29.92 | EPS CAGR: -14.52% | SUE: -0.10 | # QB: 0
Revenue Correlation: 96.36 | Revenue CAGR: 6.57% | SUE: 1.94 | # QB: 2
EPS current Quarter (2026-09-30): EPS=5.84 | Chg30d=-9.56% | Revisions=+12% | Analysts=19
EPS current Year (2026-12-31): EPS=24.38 | Chg30d=-2.59% | Revisions=-32% | GrowthEPS=+190.9% | GrowthRev=+10.6%
EPS next Year (2027-12-31): EPS=25.90 | Chg30d=+0.49% | Revisions=+28% | GrowthEPS=+6.2% | GrowthRev=+5.9%
[Analyst] Revisions Ratio: +0% (up=18, down=18)